Literature DB >> 15322159

4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function.

Seung-Joo Lee1, Lara Myers, Guruprasaadh Muralimohan, Jie Dai, Yi Qiao, Zihai Li, Robert S Mittler, Anthony T Vella.   

Abstract

CD40, 4-1BB, and OX40 are costimulatory molecules belonging to the TNF/nerve growth factor superfamily of receptors. We examined whether simultaneous costimulation affected the responses of T cells using several different in vivo tracking models in mice. We show that enforced dual costimulation through 4-1BB and OX40, but not through CD40, induced profound specific CD8 T cell clonal expansion. In contrast, the response of specific CD4 T cells to dual costimulation was additive rather than synergistic. The synergistic response of the specific CD8 T cells persevered for several weeks, and the expanded effector cells resided throughout lymphoid and nonlymphoid tissue. Dual costimulation through 4-1BB and OX40 did not increase BrdU incorporation nor an increase in the number of rounds of T cell division in comparison to single costimulators, but rather enhanced accumulation in a cell-intrinsic manner. Mechanistically speaking, we show that CD8 T cell clonal expansion and effector function did not require T help, but accumulation in (non)lymphoid tissue was predominantly CD4 T cell dependent. To determine whether this approach would be useful in a physiological setting, we demonstrated that dual costimulation mediated rejection of an established murine sarcoma. Importantly, effector function directed toward established tumors was CD8 T cell dependent while being entirely CD4 T cell independent, and the timing of enforced dual costimulation was exquisitely regulated. Collectively, these data suggest that simultaneous dual costimulation through 4-1BB and OX40 induces a massive burst of CD8 T cell effector function sufficient to therapeutically treat established tumors even under immunocompromising conditions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15322159     DOI: 10.4049/jimmunol.173.5.3002

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

Review 1.  The many sounds of T lymphocyte silence.

Authors:  Ignacio Melero; Ainhoa Arina; Lieping Chen
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 2.  Approaches to studying costimulation of human antiviral T cell responses: prospects for immunotherapeutic vaccines.

Authors:  Lena Serghides; Mariana Vidric; Tania H Watts
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

3.  The IKK-neutralizing compound Bay11 kills supereffector CD8 T cells by altering caspase-dependent activation-induced cell death.

Authors:  Seung-Joo Lee; Meixiao Long; Adam J Adler; Robert S Mittler; Anthony T Vella
Journal:  J Leukoc Biol       Date:  2008-10-15       Impact factor: 4.962

Review 4.  Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.

Authors:  Atsushi Yonezawa; Suparna Dutt; Cariad Chester; Jeewon Kim; Holbrook E Kohrt
Journal:  Clin Cancer Res       Date:  2015-04-23       Impact factor: 12.531

Review 5.  Science gone translational: the OX40 agonist story.

Authors:  Andrew D Weinberg; Nicholas P Morris; Magdalena Kovacsovics-Bankowski; Walter J Urba; Brendan D Curti
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

6.  Recruitment and in situ renewal regulate rapid accumulation of CD11c+ cells in the lung following intranasal superantigen challenge.

Authors:  Guruprasaadh Muralimohan; Robert J Rossi; Anthony T Vella
Journal:  Int Arch Allergy Immunol       Date:  2008-05-02       Impact factor: 2.749

7.  CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells.

Authors:  Shelly J Robertson; Ronald J Messer; Aaron B Carmody; Robert S Mittler; Christopher Burlak; Kim J Hasenkrug
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

8.  An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.

Authors:  Payal Mittal; Rebecca Abblett; Joseph M Ryan; Adam T Hagymasi; Archibald Agyekum-Yamoah; Julia Svedova; Steven L Reiner; Marie-Clare St Rose; Matthew P Hanley; Anthony T Vella; Adam J Adler
Journal:  J Immunol       Date:  2018-01-05       Impact factor: 5.422

9.  CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation.

Authors:  Harry Z Qui; Adam T Hagymasi; Suman Bandyopadhyay; Marie-Clare St Rose; Raghunath Ramanarasimhaiah; Antoine Ménoret; Robert S Mittler; Scott M Gordon; Steven L Reiner; Anthony T Vella; Adam J Adler
Journal:  J Immunol       Date:  2011-08-31       Impact factor: 5.422

Review 10.  Advances in the development of cancer immunotherapies.

Authors:  Jianjun Gao; Chantale Bernatchez; Padmanee Sharma; Laszlo G Radvanyi; Patrick Hwu
Journal:  Trends Immunol       Date:  2012-09-30       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.